Special Look At Phase 1b Imvax Study to Assess the Safety and Efficacy of IGV-001
Time: 4:15 pm
day: Day One
Details:
- Explore highest exposure cohort yielded significantly higher proinflammatory cytokine serum levels; by 23rd patient, clear that clinical
and radiographic responses were superior in this cohort and protocol amended for ethical reasons to stop randomization. - Deep dive with data lock, highest exposure cohort exhibiting significant improvement in both PFS and OS over historical controls.
- Study methylated subgroup manifesting a 3-fold improvement in mPFS with mOS not yet reached
